XP Chemistries - Public Comps and Valuation Multiples

XP Chemistries Overview

About XP Chemistries

XP Chemistries AB is an inventive biotechnology company that develops and patents novel nature inspired chemical processes for the production of high-quality and sustainable natural chemicals.

Founded

2015

HQ

Employees

Website

xpchemistries.com

Sectors

Chemicals

Financials

LTM Revenue $45K

LTM EBITDA -$1.0M

EV

$2.0M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

XP Chemistries Financials

As of December 2025, XP Chemistries reported last 12-month revenue of $45K and EBITDA of -$1.0M.

In the same period, XP Chemistries generated $18K in LTM gross profit and -$1.2M in net income.

See XP Chemistries valuation multiples based on analyst estimates

XP Chemistries P&L

In the most recent fiscal year, XP Chemistries reported revenue of $31K and EBITDA of -$0.8M.

XP Chemistries expects next 12-month revenue of XXX and NTM EBITDA of XXX

See XP Chemistries valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$45K	XXX	$31K	XXX	XXX	XXX
Gross Profit	$18K	XXX	$36K	XXX	XXX	XXX
Gross Margin	40%	XXX	116%	XXX	XXX	XXX
EBITDA	-$1.0M	XXX	-$0.8M	XXX	XXX	XXX
EBITDA Margin	-2150%	XXX	-2647%	XXX	XXX	XXX
EBIT	-$1.2M	XXX	-$1.0M	XXX	XXX	XXX
EBIT Margin	-2590%	XXX	-3144%	XXX	XXX	XXX
Net Profit	-$1.2M	XXX	-$0.8M	XXX	XXX	XXX
Net Margin	-2579%	XXX	-2512%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for XP Chemistries including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $45K. EBITDA for the last twelve months was -$1.0M. In the most recent fiscal year, XP Chemistries achieved $31K in revenue and -$0.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$45K	Analyst estimates available to subscribers	$31K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$18K	Analyst estimates available to subscribers	$36K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	40.2% gross margin	Analyst estimates available to subscribers	115.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$1.0M	Analyst estimates available to subscribers	-$0.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-2149.8% EBITDA margin	Analyst estimates available to subscribers	-2646.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$1.2M	Analyst estimates available to subscribers	-$1.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-2589.8% EBIT margin	Analyst estimates available to subscribers	-3144.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$1.2M	Analyst estimates available to subscribers	-$0.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-2578.8% net profit margin	Analyst estimates available to subscribers	-2512.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for XP Chemistries

This financial data table provides comprehensive performance metrics for XP Chemistries, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

XP Chemistries generated $45K in revenue over the last twelve months.
The company achieved -$1.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $18K.
Net income over the last twelve months reached -$1.2M.

Fiscal Year Performance

In the most recent fiscal year, XP Chemistries reported $31K in total revenue.
Fiscal year EBITDA was -$0.8M.
The company maintained a gross profit margin of 115.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was -2646.9%.
Net profit margin reached -2512.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for XP Chemistries. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

XP Chemistries Stock Performance

XP Chemistries has current market cap of SEK 36.6M (or $4.0M), and EV of SEK 18.6M (or $2.0M).

Market Cap Evolution

XP Chemistries Stock Data

As of January 16, 2026, XP Chemistries's stock price is SEK 0 (or $0).

See XP Chemistries trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.0M	$4.0M	XXX	XXX	XXX	XXX	$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

XP Chemistries Valuation Multiples

XP Chemistries's trades at 45.3x EV/Revenue multiple, and -2.1x EV/EBITDA.

See valuation multiples for XP Chemistries and 15K+ public comps

XP Chemistries Financial Valuation Multiples

As of January 16, 2026, XP Chemistries has market cap of $4.0M and EV of $2.0M.

Equity research analysts estimate XP Chemistries's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

XP Chemistries has a P/E ratio of -3.5x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$4.0M	XXX	$4.0M	XXX	XXX	XXX
EV (current)	$2.0M	XXX	$2.0M	XXX	XXX	XXX
EV/Revenue	45.3x	XXX	45.3x	XXX	XXX	XXX
EV/EBITDA	-2.1x	XXX	-2.1x	XXX	XXX	XXX
EV/EBIT	-1.7x	XXX	-1.7x	XXX	XXX	XXX
EV/Gross Profit	112.6x	XXX	n/a	XXX	XXX	XXX
P/E	-3.5x	XXX	-3.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-2.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get XP Chemistries Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

XP Chemistries Margins & Growth Rates

XP Chemistries's last 12 month revenue growth is 2401%

XP Chemistries's revenue per employee in the last FY averaged $10K, while opex per employee averaged $0.3M for the same period.

XP Chemistries's rule of 40 is 1091% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

XP Chemistries's rule of X is 3854% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for XP Chemistries and other 15K+ public comps

XP Chemistries Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	2401%	XXX	816%	XXX	XXX	XXX
EBITDA Margin	-2150%	XXX	-2150%	XXX	XXX	XXX
EBITDA Growth	-44%	XXX	n/a	XXX	XXX	XXX
Rule of 40	1091%	XXX	252%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	3854%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$10K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	3260%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial